SCHEMBL18050895

SCHEMBL18050895

CS(=O)(=O)c1ccc(Cn2cnc(C(N)=O)c2C(N)=O)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 1/20 0.46
PKM P14618 2/20 0.45
GAA P10253 1/20 0.45
TSHR P16473 1/20 0.45
SCD O00767 1/20 0.43
ADORA2A P29274 1/20 0.42
ADORA1 P30542 1/20 0.42
HSD17B13 Q7Z5P4 1/20 0.42
GHSR Q92847 1/20 0.41
PTGDR2 Q9Y5Y4 5/20 0.40
AURKA O14965 2/20 0.39
CCNA2 P20248 1/20 0.39
CDK2 P24941 1/20 0.39
CCNA1 P78396 1/20 0.39
ADRA1D P25100 2/20 0.38
RPS6KB1 P23443 1/20 0.38
LRRK2 Q5S007 1/20 0.38
MAP4K4 O95819 1/20 0.38
PDE4A P27815 1/20 0.37
PDE4B Q07343 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18050874 0.83 SCD (0.49) CYP11B2PKMGAATSHRSCD
SCHEMBL18050890 0.82 SCD (0.56) CYP11B2PKMGAATSHRSCD
SCHEMBL18050897 0.81 PKM (0.49) CYP11B2PKMGAATSHRSCD
SCHEMBL20591075 0.81 MAPK8 (0.48) CYP11B2PKMGAATSHRHSD17B13
SCHEMBL18050879 0.80 NPC1 (0.47) CYP11B2PKMGAATSHRSCD
SCHEMBL18050893 0.79 MEN1 (0.47) PKMGAATSHRADORA2AADORA1
SCHEMBL28151121 0.79 PKM (0.54) CYP11B2PKMGAATSHRHSD17B13
SCHEMBL18050896 0.77 PKM (0.46) PKMGAATSHRSCDADRA1D
SCHEMBL18050876 0.77 KDM4E (0.51) PKMGAATSHRSCDADORA2A
SCHEMBL18050873 0.75 SCD (0.50) CYP11B2PKMGAATSHRSCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106692138-B Application of N-benzyl imidazole amide derivative as polymyxin antibiotic synergist 广州英赛特生物技术有限公司 2020-08-04 CN disclosed
US-10435376-B2 Derivatives of 1H-imidazole-4,5-dicarboxamide and use thereof in preparation of anticoccidial drugs Guangzhou Insighter Biotechnology Co., Ltd. (CN) 2019-10-08 US disclosed
US-10435376-B2 Derivatives of 1H-imidazole-4,5-dicarboxamide and use thereof in preparation of anticoccidial drugs Guangzhou Insighter Biotechnology Co., Ltd. (CN) 2019-10-08 US disclosed
US-20180370921-A1 Derivatives of 1H-imidazole-4,5-dicarboxamide and Use Thereof in Preparation of Anticoccidial Drugs GUANGZHOU INSIGHTER BIOTECHNOLOGY CO.,LTD. (CN) 2018-12-27 US disclosed
WO-2017113525-A1 APPLICATION OF N-BENZYLIMIDAZOLECARBOXAMIDE DERIVATIVES AS SYNERGIST FOR POLYMYXIN ANTIBIOTICS 广州英赛特生物技术有限公司 2017-07-06 WO disclosed
CN-106692138-A Application of N-benzylimidamide derivative as polymyxin antibiotic synergist 广州英赛特生物技术有限公司 2017-05-24 CN disclosed
CN-104672145-B Glycalpyramide derivative and application thereof in preparing anticoccidial drug 广州英赛特生物技术有限公司 2017-04-12 CN disclosed
WO-2016141736-A1 GLYCALPYRAMIDE DERIVATIVE AND APPLICATION THEREOF IN PREPARATION OF ANTICOCCIDIAL DRUG 广州英赛特生物技术有限公司 2016-09-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180370921-A1 Derivatives of 1H-imidazole-4,5-dicarboxamide and Use Thereof in Preparation of Anticoccidial Drugs CYP3A5, DDC, CPS1 CYP11B2 406/4885PKM 938/4885GAA 1751/4885
US-10435376-B2 Derivatives of 1H-imidazole-4,5-dicarboxamide and use thereof in preparation of anticoccidial drugs CYP3A5, DDC, CPS1 CYP11B2 406/4885PKM 938/4885GAA 1751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.